{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-071477","form_type":"8-K","ticker":"AARD","cik":"0001774857","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.665212+00:00","generated_at":"2026-05-21T09:30:15.977090+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aardvark Therapeutics Q1 net loss $9.3M; cash $151.3M; Phase 3 PWS data expected early 2026","bullets":["Net loss was $9.3M in Q1 2025 vs $2.2M in Q1 2024, driven by higher R&D and G&A costs.","R&D expenses rose to $7.8M (from $1.2M) due to ARD-101 development and personnel costs.","Cash, equivalents and short-term investments totaled $151.3M; IPO net proceeds were $87.5M.","Phase 3 HERO trial of ARD-101 for Prader-Willi syndrome; top-line data readout expected early 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-071477","json":"https://secwatch.observer/filing/0000950170-25-071477.json","markdown":"https://secwatch.observer/filing/0000950170-25-071477.md","text":"https://secwatch.observer/filing/0000950170-25-071477.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1774857/000095017025071477/0000950170-25-071477-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1774857/000095017025071477/ck0001774857-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:30:15.977090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}